News
06-06-2012, 12:00 AM
bioTheranostics, developer of innovative oncology diagnostic tests and solution provider for metastatic cancer, today announced study results showing that tumor profiling with its CancerTYPE ID molecular test helped guide site-specific chemotherapy and improve overall survival for patients with carcinoma of unknown primary site.
More... (http://www.news-medical.net/news/20120606/bioTheranosticse28099-CancerTYPE-ID-molecular-test-improves-overall-survival-for-patients-with-CUP.aspx)
More... (http://www.news-medical.net/news/20120606/bioTheranosticse28099-CancerTYPE-ID-molecular-test-improves-overall-survival-for-patients-with-CUP.aspx)